Prof Pierre Conte speaks to ecancer at the BGICC 2020 conference in Cairo, Egypt about the management of patients with triple-positive breast cancer.

He explains that the prognosis of HR-positive patients is slightly better, compared to patients with HER-2 positive, HR-negative disease.

Prof Conte also the types of therapy available and the recent data from the APHINITY and ExteNET trials.